337 related articles for article (PubMed ID: 17712732)
1. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
[TBL] [Abstract][Full Text] [Related]
2. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma.
Sharma MK; Zehnbauer BA; Watson MA; Gutmann DH
Neurology; 2005 Oct; 65(8):1335-6. PubMed ID: 16247081
[No Abstract] [Full Text] [Related]
3. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
4. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
5. Pilocytic astrocytoma in a child with Noonan syndrome.
Schuettpelz LG; McDonald S; Whitesell K; Desruisseau DM; Grange DK; Gurnett CA; Wilson DB
Pediatr Blood Cancer; 2009 Dec; 53(6):1147-9. PubMed ID: 19621452
[TBL] [Abstract][Full Text] [Related]
6. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity.
Sadighi Z; Slopis J
J Child Neurol; 2013 May; 28(5):625-32. PubMed ID: 23439714
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of disseminated pilocytic astrocytomas.
Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
[TBL] [Abstract][Full Text] [Related]
9. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
10. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
[TBL] [Abstract][Full Text] [Related]
12. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas.
Ding H; Roncari L; Shannon P; Wu X; Lau N; Karaskova J; Gutmann DH; Squire JA; Nagy A; Guha A
Cancer Res; 2001 May; 61(9):3826-36. PubMed ID: 11325859
[TBL] [Abstract][Full Text] [Related]
13. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
15. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
[TBL] [Abstract][Full Text] [Related]
16. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
17. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras.
Gutmann DH; Giordano MJ; Mahadeo DK; Lau N; Silbergeld D; Guha A
Oncogene; 1996 May; 12(10):2121-7. PubMed ID: 8668337
[TBL] [Abstract][Full Text] [Related]
18. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations.
Jeuken J; van den Broecke C; Gijsen S; Boots-Sprenger S; Wesseling P
Acta Neuropathol; 2007 Aug; 114(2):121-33. PubMed ID: 17588166
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
20. BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment.
Czajkowski R
Int J Dermatol; 2011 Feb; 50(2):180-3. PubMed ID: 21244382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
